RVMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RVMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Revolution Medicines's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.30 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Revolution Medicines's Operating Income for the three months ended in Mar. 2024 was $ -140.86 Mil. Revolution Medicines's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. GuruFocus does not calculate Revolution Medicines's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Revolution Medicines's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revolution Medicines Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Interest Expense | Get a 7-Day Free Trial | -0.11 | -0.07 | -0.01 | - | -0.30 |
Revolution Medicines Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Interest Expense | Get a 7-Day Free Trial | - | - | - | -0.30 | - |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revolution Medicines (NAS:RVMD) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Revolution Medicines's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-140.86 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $79.86 Mil.
Revolution Medicines's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
GuruFocus does not calculate Revolution Medicines's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Stephen Michael Kelsey | officer: See Remarks | C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Jeff Cislini | officer: General Counsel | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Mark A Goldsmith | director, officer: See Remarks | 925 PAGE MILL ROAD, PALO ALTO CA 94304 |
Margaret A Horn | officer: See Remarks | 925 PAGE MILL ROAD, PALO ALTO CA 94304 |
Jack Anders | officer: Chief Financial Officer | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Barbara Weber | director | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Xiaolin Wang | officer: See Remarks | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Thilo Schroeder | director | C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001 |
Lorence H. Kim | director | C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472 |
Sushil Patel | director | C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801 |
Third Rock Ventures Iii, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Flavia Borellini | director | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Third Rock Ventures Ii, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Peter Svennilson | director, 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Vincent A. Miller | director | C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139 |
From GuruFocus
By Stock market mentor Stock market mentor • 02-02-2023
By Marketwired • 08-03-2023
By sperokesalga sperokesalga • 04-13-2023
By sperokesalga sperokesalga • 03-03-2023
By sperokesalga sperokesalga • 05-08-2023
By Marketwired • 10-13-2023
By sperokesalga sperokesalga • 02-21-2023
By sperokesalga sperokesalga • 05-01-2023
By GuruFocus Research • 12-10-2023
By GuruFocus Research • 10-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.